Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Initial Vancomycin Taper for the Prevention of Recurrent Clostridium Difficile Infection
NCT04138706Phase 3Completed
- Sponsor
- McGill University Health Centre
- Start
- Nov 2020
- Primary completion
- Oct 2024
- Modality
- Cyclic Peptides, Antimicrobial Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Clostridium difficile infection (CDI) comparing Control: Placebo with Intervention: Extended vancomycin regimen (2 arms). Primary endpoint: Clostridium difficile infection recurrence at 56 days. Started Nov 2020; status: completed.
02
Drugs
vancomycin
03
Conditions
Clostridium difficile infection (CDI)
Beyond the preview
Go deeper on NCT04138706.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04138706.